Company intelligence / Profile preview

DTx Pharma

San Diego, California, United Statesdtxpharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

DTx Pharma developed a proprietary siRNA delivery platform called FALCON™, enabling extrahepatic delivery and activity of RNA therapeutics. Its lead program, DTx‑1252 for CMT1A, received FDA Orphan Drug Designation and showed potent preclinical target gene repression in peripheral nerves. The company was acquired by Novartis in July 2023 to expand the latter’s neuroscience pipeline and xRNA capabilities.

Therapeutic areas: Neurology
Modalities: small interfering RNA (siRNA)oligonucleotides
Industry: Biotech

Drug pipeline

1 asset

DTx-1252

Pre-clinical

Indications: Charcot-Marie-Tooth Disease Type 1A

Beyond the preview

Go deeper on DTx Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DTx Pharma.